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Abstract The serine peptidases, thrombocytin and PA-BJ,
isolated from the venom of Bothrops atrox and Bothrops
jararaca, respectively, induce platelet aggregation and granule
secretion without clotting fibrinogen. The specific platelet
aggregation activity of each enzyme was about 15 times lower
than that of thrombin. This activity was blocked by monoclonal
antibodies recognizing protease activated receptor 1 (PAR1) and
by heparin, but not by hirudin nor thrombomodulin. Both
enzymes induced calcium mobilization in platelets and desensi-
tized platelets to the action of thrombin and the SFLLRN
peptide. We compared the effect of thrombin, PA-BJ, and
thrombocytin on the degradation of the soluble N-terminal
domain of the PAR1 receptor. The major cleavage site by
thrombin and both viper enzymes was Arg41^Ser42. In addition,
a rapid cleavage of the peptide bond at Arg46^Asn47 by the viper
enzymes was observed, resulting in the inactivation of the
tethered ligand. PA-BJ and thrombocytin both cleaved at 41^42
and 46^47 peptide bonds, and fragment 42^103 disappeared
rapidly. Both viper enzymes caused calcium mobilization in
fibroblasts transfected with PAR4 and desensitized these cells to
the thrombin action. In conclusion, both PAR1 and PAR4
mediate the effect of viper venom serine peptidases on
platelets. ß 2000 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Thrombin action on human platelets is mediated by two
protease activated receptors: PAR1 [1] and PAR4 [2,3].
Cleavage of PAR1 occurs at Arg41^Ser42 located within the
long exodomain of the receptor [4]. SFLLRN is a new amino-
terminus and functions as a tethered peptide ligand binding to
another site on the thrombin receptor and induces an intra-
cellular signaling [4]. SFLLRN mimics the new N-terminus
and acts as an agonist of platelet aggregation and secretion
[4]. Other enzymes, such as cathepsin G [5,6] and plasmin
[7,8], also cleave PAR1 at 41^42, causing its activation. In
addition, these enzymes cleave other peptide bonds in the
receptor, leading to its progressive inactivation.
Two viper venom enzymes, thrombocytin, isolated from the
venom of Bothrops atrox [9,10], and PA-BJ, isolated from
Bothrops jararaca [11], cause platelet aggregation and a release
reaction without clotting ¢brinogen. Both enzymes were puri-
¢ed into homogeneity and have a molecular weight of about
30 kDa. They are typical serine peptidases as established by
studying the hydrolysis of synthetic peptides and the e¡ect of
the inhibitors of serine and histidine active binding sites. The
full amino acid sequence of PA-BJ has been reported [11]; this
enzyme is 25 residues shorter than thrombin and shows a 31%
amino acid identity to thrombin. The comparison of the ami-
no acid sequences of PA-BJ with the sequences of other serine
peptidases allowed the putative identi¢cation of the catalytic
triad of His41, Asp86, and Ser180 in this enzyme.
The purpose of our study was to investigate the e¡ect of
these enzymes on PAR1 expressed on platelets, on the re-
combinant N-terminal domain of PAR1, and on cells trans-
fected with PAR4.
2. Materials and methods
2.1. Enzymes
Highly puri¢ed human thrombin was generously provided by Dr. J.
Fenton, Albany, NY, USA. PA-BJ was puri¢ed at the Butantan In-
stitute, Sao Paulo, Brazil, according to Serrano et al. [11]. Thrombo-
cytin was puri¢ed according to the modi¢ed method of Kirby et al. [9]
and provided by Pentapharm, Basel, Switzerland. All three prepara-
tions appeared to be homogeneous as determined by SDS^PAGE.
2.2. Monoclonal antibodies (mAb) against the thrombin receptor
mAb IIaR was provided by Biodesign, Kennebunk, ME, USA and
mAb SPAN-12 and WEDE-15 were purchased from Immunotech,
Westbrook, ME, USA. The IIaR and SPAN-12 bound to peptide
35NATLDPRSFLLR46 which contains thrombin cleavage sites be-
tween R41 and S42. The WEDE-15 antibody binds to the
51KYEPFWEDEEKNES64 motif, a hirudin binding domain in
PAR1, and is retained by PAR1 after limited proteolysis with throm-
bin [12].
2.3. Other reagents
SFLLRN peptide (TRAP) was purchased from Bachem (Torrance,
CA, USA) and thrombomodulin from American Diagnostica, Inc.
(Greenwich, CT, USA). All other reagents, including heparin, hirudin
and Fura-2-AM, were purchased from Sigma Chemical Co. (St.
Louis, MO, USA).
2.4. Human platelet suspension
Human platelet suspension was prepared by the di¡erential centri-
fugation method according to Mustard et al. [13] or by gel ¢ltration
on a Sepharose 2B column. Platelet aggregation was measured in a
Payton aggregometer. In order to study intracellular calcium mobili-
zation, platelet-rich plasma was incubated with Fura-2-acetoxymethyl
ester and separated from the non-incorporated label by di¡erential
centrifugation or gel ¢ltration. Platelet suspensions (108/ml) treated
with serine peptidases or with SFLLRN were maintained in a Perkin
Elmer LS-5 spectro£uorometer in a water-jacketed cuvette with stir-
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ring at 37‡C. Fura-2-£uorescence was monitored continuously, using
a setting of 340 nm (excitation) and 510 nm (emission). Total calcium
was estimated after cell lysis with digitonin and compared with the
calcium standard. The £uorescence was quenched by EGTA.
2.5. Recombinant soluble PAR1 domain
The human PAR1 exodomain, TR78 (residues 26^103, Mr 8925
Da) was produced in Escherichia coli at the C-terminal portion of a
fusion protein, ketosteroid isomerase, as described previously [8]. It
was puri¢ed by reverse-phase HPLC using a C-18 column and was
eluted at 35% acetonitrile. The circular dichroism and NMR spectros-
copy of TR78 suggested appropriate folding of this molecule. TR78
was solubilized at pH 7.2 in the phosphate-bu¡ered saline before
proteolytic digestion.
2.6. Digestion of PAR1 by proteolytic enzymes and separation of its
degradation products
Aliquots of TR78 at 100 Wg were incubated at room temperature
with 80 ng of thrombin or 168 ng of PA-BJ or 168 ng thrombocytin
for 2 min or 2 h. The cleavage products were then applied into a C-18
column and eluted with the acetonitrile gradient. Molecular weight of
the eluted fractions was determined by mass spectrometry (Maldi) at
the Wistar Institute, Philadelphia, PA, USA.
2.7. Fibroblasts transfected with PAR4
KF:hP4-S12 cells originated from the University of California, San
Francisco, CA, USA. The cell line was created by stably transfecting
KOLF cells with the human PAR4 gene containing a FLAG epitope
tag at its amino-terminus. KOLF cells are lung ¢broblasts from a
PAR1 knockout mouse. KF:hP4-S12 cells were grown in DME
with 10% bovine calf serum (containing 250 g hygromycin per ml)
at 37‡C in a CO2 incubator. They were labeled with Fura-2-acetoxy-
methyl ester on the cell culture plates before they reached con£uency.
After detachment of cells with a Gibco dissociation bu¡er in the
absence of proteolytic enzymes, non-bound dye Fura-2-AM elimi-
nated by gentle centrifugation and the cells were suspended in
DMEM medium [14].
3. Results and discussion
We con¢rmed that viper venom enzymes aggregated human
platelets in plasma and plasma-free suspension, and, in con-
trast to thrombin, the viper venom proteases did not clot ¢-
brinogen. Thrombin was the most potent platelet aggregating
agent. The EC50 for thrombin amounted to 0.76 nM; for PA-
BJ, it amounted to 12.5 nM, and for thrombocytin, to 4.3 nM.
SFLLRN aggregated platelets with EC50 of 120 M (data not
shown). Heparin inhibited platelet aggregation induced by all
three enzymes, whereas only thrombomodulin and hirudin
inhibited thrombin’s e¡ect (Table 1). The monoclonal anti-
body IIaR at 0.2 Wg/ml and 2.5 Wg/ml completely inhibited
the e¡ect of thrombin and venom proteases, respectively
(Table 1). Monoclonal antibodies SPAN-12 and WEDE-15
caused a weaker inhibitory e¡ect (not shown). Table 2 shows
the e¡ect of the three enzymes on calcium mobilization in
platelets and their inhibition by IIaR, SPAN-12, and
WEDE-15 antibodies. Fura labeled platelets incubated with
thrombin (0.76 nM), PA-BJ (12.5 nM), thrombocytin
(4.3 nM), and SFLLRN (120 WM) rapidly responded with
calcium mobilization and, following further incubation for
5 min, became desensitized to all agonists (not shown).
In the next series of experiments the PAR1 extracellular
domain, TR78, was digested by thrombin, PA-BJ, and throm-
bocytin for di¡erent time periods, and the incubation mixtures
were applied on HPLC column. Fig. 1 shows the elution pat-
tern of TR78 degraded by PA-BJ in an acetonitrile gradient.
Molecular weights of the eluted fragments were determined by
mass spectrometry. This permitted us to deduce the amino
acid sequences of the isolated fragments and to identify pep-
tide bonds cleaved during the digestion of the recombinant
receptor. In agreement with the previous study [8], thrombin
exclusively cleaved at the peptide bond R41^S42 up to 2 h of
incubation time, releasing two degradation products having
the molecular weights of 1783 and 7170 Da (not shown).
On the other hand, the cleavage of the R41^S42 and R46^
N47 bonds took place simultaneously after 2 min of incuba-
tion of TR78 with PA-BJ (Fig. 1). Three degradation products
separated on HPLC had molecular weights of 1783, 7170, and
6553 Da. The last fragment indicates cleavage at the site R46^
N47; this is known to inactivate the tethered thrombin recep-
tor ligand [8]. Fragment 7170 with Ser at N-terminus greatly
decreased or disappeared after 2 h incubation, being con-
verted to fragment 6553 (not shown). The incubation of
Table 1
Inhibition of thrombin and viper venom enzymes induced platelet aggregation by thrombin and viper venom serine peptidases
Agonist Inhibition %
Heparin Hirudin Thrombomodulin IIaR
100 U 12.5 U 5 nM 0.1 Wg 2.5 Wg
Thrombin 300 ng/ml 100 100 100 100 100
PA-BJ 500 ng/ml 100 0 0 10 100
Thrombocytin 500 ng/ml 100 0 0 10 100
Representative of three similar experiments.
Fig. 1. HPLC elution pattern of TR78 (100 Wg) digested with PA-
BJ (1.7 Wg) for 2 h at 37‡C. Fraction 1 corresponds to fragment
Ala26^Arg41, fragment 3 to Asn47^Leu103, and fragment 4 to
Ser42^Leu103.
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TR78 with thrombocytin resulted in the same degradation
pattern (not shown). The degradation of the tethered ligand
in the receptor by PA-BJ and by thrombocytin may explain
why these enzymes are less potent than thrombin in causing
platelet aggregation and release reaction.
To further evaluate the mechanism by which these enzymes
activate platelets, we investigated their e¡ect on calcium mo-
bilization in the suspension of lung ¢broblasts transfected
with PAR4 (cell line KF:hP4-S12). These ¢broblasts were
isolated from the lung of the mouse de¢cient in PAR1. Fig.
2 shows that the challenge of Fura-2 labeled PAR4 trans-
fected cells with thrombin (30 nM), thrombocytin (300 nM),
and PA-BJ (300 nM) resulted in a similar intracellular calcium
£ux. In addition, KF:hP4-S12 cells preincubated with venom
enzymes were desensitized to thrombin. These data indicate
that PA-BJ and thrombocytin may activate the PAR4 recep-
tor in a similar fashion to thrombin.
We conclude that both PA-BJ and thrombocytin activate
PAR1 by splitting the Arg41^Ser42 peptide bond. The lower
activity of PA-BJ and thrombocytin, as compared to throm-
bin, may result from the subsequent inactivation of PAR1 by
the venom enzymes. The venom enzymes both activate and
inactive PAR1; human plasmin has been shown to have a
similar e¡ect [8]. Matthews et al. [15] presented evidence
that thrombin binds to both Arg41^Ser42 and the hirudin
domain of PAR1 and that the binding to the hirudin domain
potentiates the proteolytic activity of thrombin. It is known
that thrombin binding to hirudin correlates with its binding to
thrombomodulin and the thrombin receptor’s hirudin do-
main. Although monoclonal antibody WEDE-15, recognizing
the hirudin binding domain in PAR1, inhibits the e¡ect of
PA-BJ and thrombocytin on the platelet, this e¡ect is not
inhibited by hirudin and thrombomodulin. Thrombomodu-
lin^hirudin binding sites [16] are located in the exosite domain
of thrombin, and thrombomodulin competes for the same
binding sites on the thrombin molecule with hirudin [17].
This exosite domain of thrombin has little homology with
corresponding regions of PA-BJ [11]. It can be hypothesized
that the PA-BJ exosite is not able to bind hirudin, thrombo-
modulin, and it binds with a lower a⁄nity to thrombin re-
ceptor hirudin’s domain. Further studies are needed to verify
this hypothesis.
Both venom enzymes can be useful tools in studies on the
structure and function of thrombin receptors. They seem to be
more selective than thrombin since they do not proteolyse and
clot ¢brinogen. Viper venom enzymes could have the advan-
tage over thrombin in studies on thrombin receptors expressed
on endothelial cells [5,18]. Thrombomodulin is a component
of endothelial cell membranes and a potent inhibitor of
thrombin e¡ects on clotting and platelet aggregation [19];
however, it has no e¡ect on platelet aggregation induced by
venom enzymes, suggesting that it does not interfere with their
e¡ect on PAR1 and PAR4.
In conclusion, we propose that the e¡ect of viper venom
serine peptidases PA-BJ and thrombocytin on platelets is
mediated both by PAR1 and by PAR4, the same receptors
which mediate the thrombin e¡ect on platelets. In contrast to
thrombin, viper venom enzymes both activate and inactivate
the receptor by removing the receptor-anchored ligand.
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